52.00
-0.70 (-1.33%)
| Previous Close | 52.70 |
| Open | 52.92 |
| Volume | 482,153 |
| Avg. Volume (3M) | 688,319 |
| Market Cap | 1,987,798,784 |
| Price / Sales | 14.70 |
| Price / Book | 8.44 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -103.64% |
| Operating Margin (TTM) | -52.29% |
| Diluted EPS (TTM) | -3.75 |
| Quarterly Revenue Growth (YOY) | 2,471.80% |
| Total Debt/Equity (MRQ) | 30.20% |
| Current Ratio (MRQ) | 5.42 |
| Operating Cash Flow (TTM) | -100.18 M |
| Levered Free Cash Flow (TTM) | -71.10 M |
| Return on Assets (TTM) | -27.26% |
| Return on Equity (TTM) | -59.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Tarsus Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.38 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 8.73% |
| % Held by Institutions | 120.74% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Sep 2024 | 1,587,527 |
| Exoduspoint Capital Management, Lp | 30 Sep 2024 | 883,043 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (Oppenheimer, 25.00%) | Buy |
| Median | 53.00 (1.92%) | |
| Low | 41.00 (Goldman Sachs, -21.15%) | Hold |
| Average | 53.00 (1.92%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 45.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 15 Nov 2024 | 41.00 (-21.15%) | Hold | 44.83 |
| Oppenheimer | 14 Nov 2024 | 65.00 (25.00%) | Buy | 46.65 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Nov 2024 | Announcement | Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors |
| 13 Nov 2024 | Announcement | Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements |
| 06 Nov 2024 | Announcement | Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 |
| 05 Nov 2024 | Announcement | Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer |
| 17 Oct 2024 | Announcement | Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% |
| 25 Sep 2024 | Announcement | Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |